Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dextallorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 10/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.86 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.69 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.69 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.69 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.69 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.69 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.69 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.69 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levallorphan SCHEMBL20505815 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL12232843 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL29368769 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL209271 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL34060 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL12233279 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL16311899 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL678413 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL8459964 | 0.99 | OPRM1 (0.98) | OPRM1OPRK1KCNH2ALDH1A1LMNA | |
| Levallorphan SCHEMBL5675160 | 0.97 | OPRM1 (0.94) | OPRM1OPRK1KCNH2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112402386-B | Abuse-preventing opioid oral sustained-release tablet and preparation method thereof | 江苏恩华药业股份有限公司 | 2022-06-28 | — | — | CN | claimed |
| US-11833167-B2 | Nicotinyl riboside compounds and their uses | MITOPOWER LLC (US) | 2023-12-05 | — | — | US | disclosed |
| CN-115916174-A | Compositions and methods for preventing stress-induced phobia, depression-like, and anxiety-like behaviors | 纽约市哥伦比亚大学理事会 | 2023-04-04 | — | — | CN | disclosed |
| CN-112402386-B | Abuse-preventing opioid oral sustained-release tablet and preparation method thereof | 江苏恩华药业股份有限公司 | 2022-06-28 | — | — | CN | disclosed |
| WO-2022074589-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREFOR | KURES, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-114173872-A | Methods and pharmaceutical compositions for treating drug overdose | 依那拉治疗股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20220062314-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MitoPower, LLC (US) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062314-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | NADK, NNT, NAMPT | OPRM1 4381/4885OPRK1 2479/4885KCNH2 3733/4885 |
| US-11833167-B2 | Nicotinyl riboside compounds and their uses | NADK, NNT, NAMPT | OPRM1 4381/4885OPRK1 2479/4885KCNH2 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.